Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07219004Not ApplicableCompleted

Artacent Amniotic Tissue for Treatment of Chronic Lower Extremity Diabetic Ulcers.

Role: lead

NCT06681428Not ApplicableRecruiting

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

Role: lead

NCT04457752Phase 4Unknown

Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)

Role: collaborator

NCT02838784Not ApplicableUnknown

Efficacy and Safety of Artacent™ for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers

Role: lead

All 4 trials loaded